Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach

27 Jun 2021

Abstract excerpt

Eltrombopag is a thrombopoietin receptor (MPL) agonist approved for the treatment of primary immune thrombocytopenia (ITP). Recent evidence shows that some patients may sustain platelet counts following eltrombopag discontinuation. The systemic immunomodulatory response that resolves ITP in some patients could result from an increase in platelet mass, caused either by the direct action of eltrombopag on...

Topics

Join the communities discussing this publication.

Blood groups and transfusion
Glycosylation and Glycoproteins Research
Platelet Disorders and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34199099
DOI: 10.3390/ijms22136907

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico ApproachPMID 34199099Read ↗

Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.Semantic proximity Read ↗

Elucidation of the Mechanisms and Molecular Targets of Yiqi Shexue Formula for Treatment of Primary Immune Thrombocytopenia Based on Network PharmacologySemantic proximity Read ↗

The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in immune thrombocytopenia.Semantic proximity Read ↗

Therapeutic potential of roxadustat in immune thrombocytopenia: a Mendelian randomization analysis.Semantic proximity Read ↗

Clusterin can mediate apoptosis-induced molecular mechanisms in immune thrombocytopeniaSemantic proximity Read ↗

Exploring biomarkers related to exosome in primary immune thrombocytopenia based on transcriptomics and experimental verificationSemantic proximity Read ↗

Knowledge map of thrombopoietin receptor agonists: A bibliometric analysisSemantic proximity Read ↗

Immune thrombocytopenia: A review of upfront treatment strategies.Semantic proximity Read ↗

Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.Semantic proximity Read ↗

Expert insights on Hodgkin's lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment.Semantic proximity Read ↗

Targeting autophagy as a potential therapeutic approach for immune thrombocytopenia therapySemantic proximity Read ↗

Decitabine improves platelet recovery by down-regulating IL-8 level in MDS/AML patients with thrombocytopeniaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.